Hepatitis B - Revision history

Michael: /* See also */

2021-12-09T15:59:33Z

Michael: PBC (newer term)

2021-09-30T21:02:11Z

PBC (newer term)

← Older revision		Revision as of 21:02, 30 September 2021
Line 7:		Line 7:
	\| Micro = lobular inflammation - hepatocyte necrosis, +/-[[ground glass hepatocytes]]		\| Micro = lobular inflammation - hepatocyte necrosis, +/-[[ground glass hepatocytes]]
	\| Subtypes =		\| Subtypes =
	\| LMDDx = [[hepatitis C]], [[autoimmune hepatitis]], [[primary biliary ~~cirrhosis~~]] without [[granulomas]], [[drug-induced liver disease\|drug reaction]]		\| LMDDx = [[hepatitis C]], [[autoimmune hepatitis]], [[primary biliary cholangitis]] without [[granulomas]], [[drug-induced liver disease\|drug reaction]]
	\| Stains = [[Shikata stain]] +ve (not sensitive)		\| Stains = [[Shikata stain]] +ve (not sensitive)
	\| IHC = hepatitis B +ve		\| IHC = hepatitis B +ve
Line 59:		Line 59:
	*[[Hepatitis C]].		*[[Hepatitis C]].
	*[[Autoimmune hepatitis]].		*[[Autoimmune hepatitis]].
	*[[Primary biliary ~~cirrhosis~~]] without [[granulomas]].		*[[Primary biliary cholangitis]] without [[granulomas]].
	*[[Drug-induced liver disease\|Drug reaction]].		*[[Drug-induced liver disease\|Drug reaction]].
	**Pseudo-Lafora bodies in patients on disulfiram (anatabuse) can result in [[ground glass hepatocytes]].		**Pseudo-Lafora bodies in patients on disulfiram (anatabuse) can result in [[ground glass hepatocytes]].

Michael at 14:10, 12 December 2017

2017-12-12T14:10:43Z

← Older revision		Revision as of 14:10, 12 December 2017
Line 28:		Line 28:
	\| Prognosis =		\| Prognosis =
	\| Other =		\| Other =
	\| ClinDDx =		\| ClinDDx = other hepatitides - viral and non-viral
	\| Tx =		\| Tx = prevention through vaccination, medical treatments (pegylated interferon and nucleoside analogues)
	}}		}}
	'''Hepatitis B''' is a relatively common [[medical liver disease]] caused by the ''hepatitis B virus''.		'''Hepatitis B''' is a relatively common [[medical liver disease]] caused by the ''hepatitis B virus''.
Line 38:		Line 38:
	*Diagnosis is by serology - details of serologic testing are in the ''[[Medical_liver_disease#Hepatitis_B\|medical liver disease article]]''.		*Diagnosis is by serology - details of serologic testing are in the ''[[Medical_liver_disease#Hepatitis_B\|medical liver disease article]]''.
	*A vaccination is available and done routinely in a many jurisdictions.<ref name=pmid21653306>{{Cite journal \| last1 = Leuridan \| first1 = E. \| last2 = Van Damme \| first2 = P. \| title = Hepatitis B and the need for a booster dose. \| journal = Clin Infect Dis \| volume = 53 \| issue = 1 \| pages = 68-75 \| month = Jul \| year = 2011 \| doi = 10.1093/cid/cir270 \| PMID = 21653306 }}</ref>		*A vaccination is available and done routinely in a many jurisdictions.<ref name=pmid21653306>{{Cite journal \| last1 = Leuridan \| first1 = E. \| last2 = Van Damme \| first2 = P. \| title = Hepatitis B and the need for a booster dose. \| journal = Clin Infect Dis \| volume = 53 \| issue = 1 \| pages = 68-75 \| month = Jul \| year = 2011 \| doi = 10.1093/cid/cir270 \| PMID = 21653306 }}</ref>
	*Medical treatments available for chronic infection - nucleoside analogue ~~(NUC) and pegylated interferon~~ therapies.<ref>{{Cite journal \| last1 = Su \| first1 = TH. \| last2 = Kao \| first2 = JH. \| title = Unmet Needs in Clinical and Basic Hepatitis B Virus Research. \| journal = J Infect Dis \| volume = 216 \| issue = suppl_8 \| pages = S750-S756 \| month = Nov \| year = 2017 \| doi = 10.1093/infdis/jix382 \| PMID = 29156048 }}</ref><ref name=pmid28052634>{{Cite journal \| last1 = Chen \| first1 = GF. \| last2 = Wang \| first2 = C. \| last3 = Lau \| first3 = G. \| title = Treatment of chronic hepatitis B infection-2017. \| journal = Liver Int \| volume = 37 Suppl 1 \| issue = \| pages = 59-66 \| month = Jan \| year = 2017 \| doi = 10.1111/liv.13309 \| PMID = 28052634 }}</ref>		*Medical treatments available for chronic infection - pegylated interferon and nucleoside analogue therapies.<ref>{{Cite journal \| last1 = Su \| first1 = TH. \| last2 = Kao \| first2 = JH. \| title = Unmet Needs in Clinical and Basic Hepatitis B Virus Research. \| journal = J Infect Dis \| volume = 216 \| issue = suppl_8 \| pages = S750-S756 \| month = Nov \| year = 2017 \| doi = 10.1093/infdis/jix382 \| PMID = 29156048 }}</ref><ref name=pmid28052634>{{Cite journal \| last1 = Chen \| first1 = GF. \| last2 = Wang \| first2 = C. \| last3 = Lau \| first3 = G. \| title = Treatment of chronic hepatitis B infection-2017. \| journal = Liver Int \| volume = 37 Suppl 1 \| issue = \| pages = 59-66 \| month = Jan \| year = 2017 \| doi = 10.1111/liv.13309 \| PMID = 28052634 }}</ref>

	===Associated pathology===		===Associated pathology===

Michael: /* General */

2017-12-12T14:07:30Z

General

← Older revision		Revision as of 14:07, 12 December 2017
Line 37:		Line 37:
	*High prevalence.		*High prevalence.
	*Diagnosis is by serology - details of serologic testing are in the ''[[Medical_liver_disease#Hepatitis_B\|medical liver disease article]]''.		*Diagnosis is by serology - details of serologic testing are in the ''[[Medical_liver_disease#Hepatitis_B\|medical liver disease article]]''.
	*A vaccination is available and done routinely in a many jurisdictions.<ref>{{Cite journal \| last1 = Leuridan \| first1 = E. \| last2 = Van Damme \| first2 = P. \| title = Hepatitis B and the need for a booster dose. \| journal = Clin Infect Dis \| volume = 53 \| issue = 1 \| pages = 68-75 \| month = Jul \| year = 2011 \| doi = 10.1093/cid/cir270 \| PMID = 21653306 }}</ref>		*A vaccination is available and done routinely in a many jurisdictions.<ref name=pmid21653306>{{Cite journal \| last1 = Leuridan \| first1 = E. \| last2 = Van Damme \| first2 = P. \| title = Hepatitis B and the need for a booster dose. \| journal = Clin Infect Dis \| volume = 53 \| issue = 1 \| pages = 68-75 \| month = Jul \| year = 2011 \| doi = 10.1093/cid/cir270 \| PMID = 21653306 }}</ref>
			*Medical treatments available for chronic infection - nucleoside analogue (NUC) and pegylated interferon therapies.<ref>{{Cite journal \| last1 = Su \| first1 = TH. \| last2 = Kao \| first2 = JH. \| title = Unmet Needs in Clinical and Basic Hepatitis B Virus Research. \| journal = J Infect Dis \| volume = 216 \| issue = suppl_8 \| pages = S750-S756 \| month = Nov \| year = 2017 \| doi = 10.1093/infdis/jix382 \| PMID = 29156048 }}</ref><ref name=pmid28052634>{{Cite journal \| last1 = Chen \| first1 = GF. \| last2 = Wang \| first2 = C. \| last3 = Lau \| first3 = G. \| title = Treatment of chronic hepatitis B infection-2017. \| journal = Liver Int \| volume = 37 Suppl 1 \| issue = \| pages = 59-66 \| month = Jan \| year = 2017 \| doi = 10.1111/liv.13309 \| PMID = 28052634 }}</ref>

	Associated pathology:		===Associated pathology===
	*[[Polyarteritis nodosa]] (PAN).		*[[Polyarteritis nodosa]] (PAN).
	*[[Membranoproliferative glomerulonephritis]].		*[[Membranoproliferative glomerulonephritis]].
	*[[Membranous nephropathy]].		*[[Membranous nephropathy]].
			*[[Cirrhosis]].
			*[[Hepatocellular carcinoma]].

	==Microscopic==		==Microscopic==

Michael at 13:59, 12 December 2017

2017-12-12T13:59:15Z

← Older revision		Revision as of 13:59, 12 December 2017
Line 8:		Line 8:
	\| Subtypes =		\| Subtypes =
	\| LMDDx = [[hepatitis C]], [[autoimmune hepatitis]], [[primary biliary cirrhosis]] without [[granulomas]], [[drug-induced liver disease\|drug reaction]]		\| LMDDx = [[hepatitis C]], [[autoimmune hepatitis]], [[primary biliary cirrhosis]] without [[granulomas]], [[drug-induced liver disease\|drug reaction]]
	\| Stains =		\| Stains = [[Shikata stain]] +ve (not sensitive)
	\| IHC =		\| IHC = hepatitis B +ve
	\| EM =		\| EM =
	\| Molecular =		\| Molecular = HBV DNA present (serum)
	\| IF =		\| IF =
	\| Gross =		\| Gross =

Michael at 13:56, 12 December 2017

2017-12-12T13:56:34Z

← Older revision		Revision as of 13:56, 12 December 2017
Line 23:		Line 23:
	\| Symptoms =		\| Symptoms =
	\| Prevalence = common - especially in Asia		\| Prevalence = common - especially in Asia
	\| Bloodwork =		\| Bloodwork = HBs Ag, HBs Ab, HBe Ag, HBe Ab - see ''[[Medical_liver_disease#Hepatitis_B]]''
	\| Rads =		\| Rads =
	\| Endoscopy =		\| Endoscopy =

Michael at 13:54, 12 December 2017

2017-12-12T13:54:19Z

← Older revision		Revision as of 13:54, 12 December 2017
Line 7:		Line 7:
	\| Micro = lobular inflammation - hepatocyte necrosis, +/-[[ground glass hepatocytes]]		\| Micro = lobular inflammation - hepatocyte necrosis, +/-[[ground glass hepatocytes]]
	\| Subtypes =		\| Subtypes =
	\| LMDDx = [[hepatitis C]], [[autoimmune hepatitis]], [[primary biliary cirrhosis]] without [[granulomas]], [[drug-induced liver disease\|~~Drug~~ reaction]]		\| LMDDx = [[hepatitis C]], [[autoimmune hepatitis]], [[primary biliary cirrhosis]] without [[granulomas]], [[drug-induced liver disease\|drug reaction]]
	\| Stains =		\| Stains =
	\| IHC =		\| IHC =

Michael: /* Microscopic */

2017-12-12T13:53:43Z

Microscopic

← Older revision		Revision as of 13:53, 12 December 2017
Line 58:		Line 58:
	*[[Primary biliary cirrhosis]] without [[granulomas]].		*[[Primary biliary cirrhosis]] without [[granulomas]].
	*[[Drug-induced liver disease\|Drug reaction]].		*[[Drug-induced liver disease\|Drug reaction]].
			**Pseudo-Lafora bodies in patients on disulfiram (anatabuse) can result in [[ground glass hepatocytes]].

	===Image===		===Image===

Michael at 13:52, 12 December 2017

2017-12-12T13:52:30Z

← Older revision		Revision as of 13:52, 12 December 2017
Line 1:		Line 1:
	{{ Infobox diagnosis		{{ Infobox diagnosis
	\| Name = {{PAGENAME}}		\| Name = {{PAGENAME}}
	\| Image =		\| Image = Ground_glass_hepatocytes_high_mag_cropped_2.jpg
	\| Width =		\| Width =
	\| Caption =		\| Caption = Ground glass hepatocytes in chronic hepatitis B. [[H&E stain]].
	\| Synonyms =		\| Synonyms =
	\| Micro = lobular inflammation - hepatocyte necrosis, +/-[[ground glass hepatocytes]]		\| Micro = lobular inflammation - hepatocyte necrosis, +/-[[ground glass hepatocytes]]

Michael: +tmplate

2017-12-12T13:51:54Z

+tmplate

← Older revision		Revision as of 13:51, 12 December 2017
Line 1:		Line 1:
			{{ Infobox diagnosis
			\| Name = {{PAGENAME}}
			\| Image =
			\| Width =
			\| Caption =
			\| Synonyms =
			\| Micro = lobular inflammation - hepatocyte necrosis, +/-[[ground glass hepatocytes]]
			\| Subtypes =
			\| LMDDx = [[hepatitis C]], [[autoimmune hepatitis]], [[primary biliary cirrhosis]] without [[granulomas]], [[drug-induced liver disease\|Drug reaction]]
			\| Stains =
			\| IHC =
			\| EM =
			\| Molecular =
			\| IF =
			\| Gross =
			\| Grossing =
			\| Staging =
			\| Site = [[liver]] - see ''[[medical liver disease]]''
			\| Assdx = [[cirrhosis]], [[hepatocellular carcinoma]], [[polyarteritis nodosa]] (PAN), [[membranoproliferative glomerulonephritis]], [[membranous nephropathy]]
			\| Syndromes =
			\| Clinicalhx =
			\| Signs =
			\| Symptoms =
			\| Prevalence = common - especially in Asia
			\| Bloodwork =
			\| Rads =
			\| Endoscopy =
			\| Prognosis =
			\| Other =
			\| ClinDDx =
			\| Tx =
			}}
	'''Hepatitis B''' is a relatively common [[medical liver disease]] caused by the ''hepatitis B virus''.		'''Hepatitis B''' is a relatively common [[medical liver disease]] caused by the ''hepatitis B virus''.

← Older revision		Revision as of 15:59, 9 December 2021
Line 110:		Line 110:
	==See also==		==See also==
	*[[Medical liver disease]].		*[[Medical liver disease]].
			*[[Viruses and cancer]].

	==References==		==References==